Prediction of drug concentration-time profiles of therapeutic proteins in humans from animals

References

• Adams CW, Allison DE, Flagella K, Presta L, Clarke J, Dybdal N, McKeever K, Sliwkowski MX. (2006). Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother 55:717–727.
   PubMed Web of Science ®Google Scholar
• Adelman D. (2001). Phase I safety and pharmacokinetic study of recombinant human anti- vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19:843–850.
   PubMedGoogle Scholar
• Agus DB, Gordon MS, Taylor C, Natale RB, Karlan B, Mendelson DS, Press MF, Allison DE, Sliwkowski MX, Lieberman G, Kelsey SM, Fyfe G. (2005). Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 23:2534–2543.
   PubMed Web of Science ®Google Scholar
• Bleuel H, Hoffmann R, Kaufmann B, Neubert P, Ochlich PP, Schaumann W. (1996). Kinetics of subcutaneous versus intravenous epoetin-β in dogs, rats and mice. Pharmacology 52:329–338.
   PubMed Web of Science ®Google Scholar
• Boxenbaum H. (1982). Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 10:201–227.
   PubMedGoogle Scholar
• Boxenbaum H. (1984). Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm. Drug Metab Rev 15:1071–1121.
   PubMed Web of Science ®Google Scholar
• Boxenbaum H, Ronfeld R. (1983). Interspecies pharmacokinetic scaling and the Dedrick plots. Am J Physiol 245:R768–R775.
   PubMed Web of Science ®Google Scholar
• Chakraborty A, Tannenbaum S, Rordorf C, Lowe PJ, Floch D, Gram H, Roy S. (2012). Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody. Clin Pharmacokinet 1 51:e1–e18.
   Google Scholar
• Davis CB, Hepburn TW, Urbanski JJ, Kwok DC, Hart TK, Herzyk DJ, Demuth SG, Leland M, Rhodes GR. (1995). Preclinical pharmacokinetic evaluation of the respiratory syncytial virus-specific reshaped human monoclonal antibody RSHZ19. Drug Metab Dispos 23:1028–1036.
   PubMed Web of Science ®Google Scholar
• Dedrick R, Bischoff KB, Zaharko DS. (1970). Interspecies correlation of plasma concentration history of methotrexate (NSC-740). Cancer Chemother Rep 54:95–101.
   PubMedGoogle Scholar
• Ducongé J, Fernández-Sánchez E, Alvarez D. (2004). Interspecies scaling of the monoclonal anti-EGF receptor ior EGF/r3 antibody disposition using allometric paradigm: is it really suitable? Biopharm Drug Dispos 25:177–186.
   PubMed Web of Science ®Google Scholar
• Everitt DE, Davis CB, Thompson K, DiCicco R, Ilson B, Demuth SG, Herzyk DJ, Jorkasky DK. (1996). The pharmacokinetics, antigenicity, and fusion-inhibition activity of RSHZ19, a humanized monoclonal antibody to respiratory syncytial virus, in healthy volunteers. J Infect Dis 174:463–469.
   PubMed Web of Science ®Google Scholar
• Fernandez-Sánchez E, Ducongé J, Castillo R, Garcia I, Beausoleil I, Macías A. (2002). Monoclonal anti-epidermal growth factor receptor (ior EGF/r3) antibody pharmacokinetic studies on nude mice I: a radio-receptor analysis applied to drug serum quantification. J Pharm Pharmacol 54:59–64.
   PubMed Web of Science ®Google Scholar
• Flaharty KK, Caro J, Erslev A, Whalen JJ, Morris EM, Bjornsson TD, Vlasses PH. (1990). Pharmacokinetics and erythropoietic response to human recombinant erythropoietin in healthy men. Clin Pharmacol Ther 47:557–564.
   PubMed Web of Science ®Google Scholar
• Gordon MS, Margolin K, Talpaz M, Sledge GW Jr, Holmgren E, Benjamin R, Stalter S, Shak S, Adelman D. (2001). Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19:843–850.
   PubMed Web of Science ®Google Scholar
• Lin YS, Nguyen C, Mendoza JL, Escandon E, Fei D, Meng YG, Modi NB. (1999). Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 288:371–378.
   PubMed Web of Science ®Google Scholar
• Mahmood I. (2009). Pharmacokinetic allometric scaling of antibodies: application to the first-in-human dose estimation. J Pharm Sci 98:3850–3861.
   PubMed Web of Science ®Google Scholar
• Mahmood I. (2004). Interspecies scaling of protein drugs: prediction of clearance from animals to humans. J Pharm Sci 93:177–185.
   PubMed Web of Science ®Google Scholar
• Mahmood I. (1999). Prediction of clearance, volume of distribution and half-life by allometric scaling and by use of plasma concentrations predicted from pharmacokinetic constants: a comparative study. J Pharm Pharmacol 51:905–910.
   PubMedGoogle Scholar
• Mahmood I, Balian JD. (1996). Interspecies scaling: predicting clearance of drugs in humans. Three different approaches. Xenobiotica 26:887–895.
   PubMed Web of Science ®Google Scholar
• Mahmood I, Yuan R. (1999). A comparative study of allometric scaling with plasma concentrations predicted by species-invariant time methods. Biopharm Drug Dispos 20:137–144.
   PubMed Web of Science ®Google Scholar
• Mahmood I, Goteti K. (2012). Prediction of drug concentration-time data in humans from animals: a comparison of three methods. Xenobiotica Feb 24. [Epub ahead of print]
   Google Scholar
• Markwardt F, Nowak G, Stürzebecher J, Vogel G. (1988). Clinico-pharmacological studies with recombinant hirudin. Thromb Res 52:393–400.
   PubMed Web of Science ®Google Scholar
• Mordenti J. (1985). Pharmacokinetic scale-up: accurate prediction of human pharmacokinetic profiles from animal data. J Pharm Sci 74:1097–1099.
   PubMed Web of Science ®Google Scholar
• Nowak G. (1991). Pharmacokinetics of hirudin. Semin Thromb Hemost 17:145–149.
   PubMed Web of Science ®Google Scholar
• Swabb EA, Bonner DP. (1983). Prediction of aztreonam pharmacokinetics in humans based on data from animals. J Pharmacokinet Biopharm 11:215–223.
   PubMedGoogle Scholar
• Wajima T, Yano Y, Fukumura K, Oguma T. (2004). Prediction of human pharmacokinetic profile in animal scale up based on normalizing time course profiles. J Pharm Sci 93:1890–1900.
   PubMed Web of Science ®Google Scholar